Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands

Hans M. Westgeest; Malou C. P. Kuppen; Alphonsus J. M. van den Eertwegh; Ronald de Wit; Juleon L. L. M. Coenen; H. P. (Pieter) van den Berg; Niven Mehra; Inge M. van Oort; Laurent M. C. L. Fossion; Mathijs P. Hendriks; Haiko J. Bloemendal; Addy C. M. van de Luijtgaarden; Daan ten Bokkel Huinink; A. C. M. (Fons) van den Bergh; Joan van den Bosch; Marco B. Polee; Nir Weijl; Andre M. Bergman; Carin A. Uyl-de Groot; Winald R. Gerritsen

doi:10.1016/j.clgc.2019.05.018

Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands

Hans M. Westgeest, Malou C. P. Kuppen, Alphonsus J. M. van den Eertwegh, Ronald de Wit, Juleon L. L. M. Coenen, H. P. (Pieter) van den Berg, Niven Mehra, Inge M. van Oort, Laurent M. C. L. Fossion, Mathijs P. Hendriks, Haiko J. Bloemendal, Addy C. M. van de Luijtgaarden, Daan ten Bokkel Huinink, A. C. M. (Fons) van den Bergh, Joan van den Bosch, Marco B. Polee, Nir Weijl, Andre M. Bergman, Carin A. Uyl-de Groot, Winald R. Gerritsen

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

In the Dutch CAPRI registry, cabazitaxel treatment as the standard of care and in trials was analyzed. Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily practice showed features of more aggressive disease and worse outcome. This may be explained by a worse prognosis at cabazitaxel initiation.

Original language	English
Pages (from-to)	e946-e956
Journal	Clinical Genitourinary Cancer
Volume	17
Issue number	5
DOIs	https://doi.org/10.1016/j.clgc.2019.05.018
Publication status	Published - 1 Oct 2019

Access to Document

10.1016/j.clgc.2019.05.018

Cite this

Westgeest, H. M., Kuppen, M. C. P., van den Eertwegh, A. J. M., de Wit, R., Coenen, J. L. L. M., van den Berg, H. P. P., ... Gerritsen, W. R. (2019). Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. Clinical Genitourinary Cancer, 17(5), e946-e956. https://doi.org/10.1016/j.clgc.2019.05.018

Westgeest, Hans M. ; Kuppen, Malou C. P. ; van den Eertwegh, Alphonsus J. M. ; de Wit, Ronald ; Coenen, Juleon L. L. M. ; van den Berg, H. P. (Pieter) ; Mehra, Niven ; van Oort, Inge M. ; Fossion, Laurent M. C. L. ; Hendriks, Mathijs P. ; Bloemendal, Haiko J. ; van de Luijtgaarden, Addy C. M. ; ten Bokkel Huinink, Daan ; van den Bergh, A. C. M. (Fons) ; van den Bosch, Joan ; Polee, Marco B. ; Weijl, Nir ; Bergman, Andre M. ; Uyl-de Groot, Carin A. ; Gerritsen, Winald R. / Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. In: Clinical Genitourinary Cancer. 2019 ; Vol. 17, No. 5. pp. e946-e956.

@article{7d5730a2f19e452fb568acb8f901f551,

title = "Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands",

abstract = "In the Dutch CAPRI registry, cabazitaxel treatment as the standard of care and in trials was analyzed. Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily practice showed features of more aggressive disease and worse outcome. This may be explained by a worse prognosis at cabazitaxel initiation.",

author = "Westgeest, {Hans M.} and Kuppen, {Malou C. P.} and {van den Eertwegh}, {Alphonsus J. M.} and {de Wit}, Ronald and Coenen, {Juleon L. L. M.} and {van den Berg}, {H. P. (Pieter)} and Niven Mehra and {van Oort}, {Inge M.} and Fossion, {Laurent M. C. L.} and Hendriks, {Mathijs P.} and Bloemendal, {Haiko J.} and {van de Luijtgaarden}, {Addy C. M.} and {ten Bokkel Huinink}, Daan and {van den Bergh}, {A. C. M. (Fons)} and {van den Bosch}, Joan and Polee, {Marco B.} and Nir Weijl and Bergman, {Andre M.} and {Uyl-de Groot}, {Carin A.} and Gerritsen, {Winald R.}",

year = "2019",

month = "10",

day = "1",

doi = "10.1016/j.clgc.2019.05.018",

language = "English",

volume = "17",

pages = "e946--e956",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier",

number = "5",

}

Westgeest, HM, Kuppen, MCP, van den Eertwegh, AJM, de Wit, R, Coenen, JLLM, van den Berg, HPP, Mehra, N, van Oort, IM, Fossion, LMCL, Hendriks, MP, Bloemendal, HJ, van de Luijtgaarden, ACM, ten Bokkel Huinink, D, van den Bergh, ACMF, van den Bosch, J, Polee, MB, Weijl, N, Bergman, AM, Uyl-de Groot, CA & Gerritsen, WR 2019, 'Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands', Clinical Genitourinary Cancer, vol. 17, no. 5, pp. e946-e956. https://doi.org/10.1016/j.clgc.2019.05.018

Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. / Westgeest, Hans M.; Kuppen, Malou C. P.; van den Eertwegh, Alphonsus J. M.; de Wit, Ronald; Coenen, Juleon L. L. M.; van den Berg, H. P. (Pieter); Mehra, Niven; van Oort, Inge M.; Fossion, Laurent M. C. L.; Hendriks, Mathijs P.; Bloemendal, Haiko J.; van de Luijtgaarden, Addy C. M.; ten Bokkel Huinink, Daan; van den Bergh, A. C. M. (Fons); van den Bosch, Joan; Polee, Marco B.; Weijl, Nir; Bergman, Andre M.; Uyl-de Groot, Carin A.; Gerritsen, Winald R.

In: Clinical Genitourinary Cancer, Vol. 17, No. 5, 01.10.2019, p. e946-e956.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands

AU - Westgeest, Hans M.

AU - Kuppen, Malou C. P.

AU - van den Eertwegh, Alphonsus J. M.

AU - de Wit, Ronald

AU - Coenen, Juleon L. L. M.

AU - van den Berg, H. P. (Pieter)

AU - Mehra, Niven

AU - van Oort, Inge M.

AU - Fossion, Laurent M. C. L.

AU - Hendriks, Mathijs P.

AU - Bloemendal, Haiko J.

AU - van de Luijtgaarden, Addy C. M.

AU - ten Bokkel Huinink, Daan

AU - van den Bergh, A. C. M. (Fons)

AU - van den Bosch, Joan

AU - Polee, Marco B.

AU - Weijl, Nir

AU - Bergman, Andre M.

AU - Uyl-de Groot, Carin A.

AU - Gerritsen, Winald R.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - In the Dutch CAPRI registry, cabazitaxel treatment as the standard of care and in trials was analyzed. Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily practice showed features of more aggressive disease and worse outcome. This may be explained by a worse prognosis at cabazitaxel initiation.

AB - In the Dutch CAPRI registry, cabazitaxel treatment as the standard of care and in trials was analyzed. Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily practice showed features of more aggressive disease and worse outcome. This may be explained by a worse prognosis at cabazitaxel initiation.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85070706340&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31439536

U2 - 10.1016/j.clgc.2019.05.018

DO - 10.1016/j.clgc.2019.05.018

M3 - Article

C2 - 31439536

VL - 17

SP - e946-e956

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 5

ER -